Co-founder & CSO Parag Mallick Granted 280,000 Options, Maintains 17.6% Stake
Summary
Nautilus Biotechnology's Co-founder and Chief Science Officer, Parag Mallick, was granted 280,000 stock options, reinforcing his significant 17.6% beneficial ownership in the company.
Key Events
-
Insider Option Grant
Co-founder and Chief Science Officer Parag Mallick was granted options to purchase 280,000 shares of common stock on March 2, 2026.
-
Significant Ownership Stake
Dr. Mallick's beneficial ownership now stands at 22,557,411 shares, representing 17.6% of the company's outstanding common stock.
-
Updated Disclosure
This filing amends previous Schedule 13D disclosures, providing an updated view of a key executive's stake and recent compensation.
Analysis
This Schedule 13D/A filing updates the beneficial ownership of Parag Mallick, Co-founder and Chief Science Officer, to 17.6% of Nautilus Biotechnology's outstanding shares. The key new event is the grant of 280,000 stock options to Dr. Mallick on March 2, 2026. This grant, valued at approximately $764,400 based on the current stock price, serves as a significant compensation component and further aligns his interests with long-term shareholder value. His substantial ownership stake, combined with this new option grant, signals strong insider commitment to the company's future.
At the time of this filing, NAUT was trading at $2.73 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $331.6M. The 52-week trading range was $0.62 to $3.08. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.